- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novo Nordisk Ponders US Plant to Make Oral Therapy
Semaglutide is currently available as an injectible only, but the company is working on a once-daily pill form.
The world’s largest maker of insulin told Bloomberg today that it is weighing whether to build a plant in the United States to make an oral version of semaglutide, a GLP-1 therapy to treat type 2 diabetes mellitus (T2DM).
The move would target the expected demand for treatments for T2DM in the United States as the epidemic here continues and the population here ages. It would also protect the Danish drugmaker against fluctuations in the US dollar, according to the report.
Last month, Novo Nordisk announced it had achieved successful phase 3a results with the injectable version of semaglutide, a glucagon-like peptide analogue administered once weekly. The company is also developing an oral version, and the report said that if successful it would be one of several therapies that would “revolutionize” the drugmaker.
A decision on whether to build a plant in the United States would depend on whether oral semaglutide were approved and sold in this country, Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen told Bloomberg.
The company has existing facilities in North Carolina and New Hampshire but declined to say whether a new plant would be built in those states or elsewhere. According to the company, its plant in Kalundborg, Denmark, employs 2800 people and makes insulin for half the world’s diabetics.
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
